Pipeline Watch: Top-Line Lanadelumab, Inotersen, Durvalumab Results

 
• By John Davis
  
Pipeline Watch regular column feature image
Clinical Trial News • Source: Biomedtracker

More from Pipeline Watch

More from R&D